94 related articles for article (PubMed ID: 27906878)
21. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
[TBL] [Abstract][Full Text] [Related]
22. The Glasgow Prognostic Score. An useful tool to predict survival in patients with advanced esophageal squamous cell carcinoma.
Henry MA; Lerco MM; de Oliveira WK; Guerra AR; Rodrigues MA
Acta Cir Bras; 2015 Aug; 30(8):580-5. PubMed ID: 26352339
[TBL] [Abstract][Full Text] [Related]
23. Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy.
Wang CY; Hsieh MJ; Chiu YC; Li SH; Huang HW; Fang FM; Huang YJ
Radiother Oncol; 2009 Aug; 92(2):270-5. PubMed ID: 19195729
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients.
Wang Z; Liu H; Shen Z; Wang X; Zhang H; Qin J; Xu J; Sun Y; Qin X
BMC Cancer; 2015 Oct; 15():766. PubMed ID: 26497045
[TBL] [Abstract][Full Text] [Related]
25. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer.
Guillem P; Triboulet JP
Dis Esophagus; 2005; 18(3):146-50. PubMed ID: 16045574
[TBL] [Abstract][Full Text] [Related]
26. C-reactive protein 1059G>C genetic polymorphism influences serum C-reactive protein levels after esophagectomy in patients with thoracic esophageal cancer.
Motoyama S; Miura M; Hinai Y; Maruyama K; Usami S; Nakatsu T; Saito H; Minamiya Y; Suzuki T; Ogawa J
J Am Coll Surg; 2009 Oct; 209(4):477-83. PubMed ID: 19801321
[TBL] [Abstract][Full Text] [Related]
27. CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma.
Li L; Xu L; Yan J; Zhen ZJ; Ji Y; Liu CQ; Lau WY; Zheng L; Xu J
J Exp Clin Cancer Res; 2015 Oct; 34():129. PubMed ID: 26503598
[TBL] [Abstract][Full Text] [Related]
28. Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas.
Liu C; Ma H; Qu L; Wu J; Meng L; Shou C
Hepatogastroenterology; 2012 Oct; 59(119):2222-7. PubMed ID: 22440249
[TBL] [Abstract][Full Text] [Related]
29. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
Knychalski B; Lukieńczuk T
Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
[TBL] [Abstract][Full Text] [Related]
30. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer.
Kawamura M; Toiyama Y; Tanaka K; Saigusa S; Okugawa Y; Hiro J; Uchida K; Mohri Y; Inoue Y; Kusunoki M
Eur J Cancer; 2012 Sep; 48(14):2244-51. PubMed ID: 22197219
[TBL] [Abstract][Full Text] [Related]
31. Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma.
Ikeda M; Natsugoe S; Ueno S; Baba M; Aikou T
Ann Surg; 2003 Aug; 238(2):197-202. PubMed ID: 12894012
[TBL] [Abstract][Full Text] [Related]
32. A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio.
Wei XL; Wang FH; Zhang DS; Qiu MZ; Ren C; Jin Y; Zhou YX; Wang DS; He MM; Bai L; Wang F; Luo HY; Li YH; Xu RH
BMC Cancer; 2015 May; 15():350. PubMed ID: 25934640
[TBL] [Abstract][Full Text] [Related]
33. The influence of elevated levels of C-reactive protein and hypoalbuminemia on survival in patients with advanced inoperable esophageal cancer undergoing palliative treatment.
Lindenmann J; Fink-Neuboeck N; Koesslbacher M; Pichler M; Stojakovic T; Roller RE; Maier A; Anegg U; Smolle J; Smolle-Juettner FM
J Surg Oncol; 2014 Nov; 110(6):645-50. PubMed ID: 24975677
[TBL] [Abstract][Full Text] [Related]
34. Plasma DNA is more reliable than carcinoembryonic antigen for diagnosis of recurrent esophageal cancer.
Banki F; Yacoub WN; Hagen JA; Mason RJ; Ayazi S; DeMeester SR; Lipham JC; Danenberg K; Danenberg P; DeMeester TR
J Am Coll Surg; 2008 Jul; 207(1):30-5. PubMed ID: 18589358
[TBL] [Abstract][Full Text] [Related]
35. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer.
Wang B; Hendricks DT; Wamunyokoli F; Parker MI
Cancer Res; 2006 Mar; 66(6):3071-7. PubMed ID: 16540656
[TBL] [Abstract][Full Text] [Related]
36. [Significance of CEA, SCC and Cyfra21-1 serum test in esophageal cancer].
Mao YS; Zhang DC; Zhao XH; Wang LJ; Qi J; Li XX
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):457-60. PubMed ID: 14575569
[TBL] [Abstract][Full Text] [Related]
37. Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma.
Liu Z; Yang L; Xu J; Zhang X; Wang B
J Surg Res; 2011 Apr; 166(2):241-6. PubMed ID: 20018298
[TBL] [Abstract][Full Text] [Related]
38. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
39. Soluble interleukin-2 receptor in serum of patients with esophageal carcinoma.
Jabłońska E; Kozłowski M; Pietruska Z; Furman M
Neoplasma; 1994; 41(6):315-8. PubMed ID: 7870214
[TBL] [Abstract][Full Text] [Related]
40. Association of CXCR1 and 2 expressions with gastric cancer metastasis in ex vivo and tumor cell invasion in vitro.
Li Z; Wang Y; Dong S; Ge C; Xiao Y; Li R; Ma X; Xue Y; Zhang Q; Lv J; Tan Q; Zhu Z; Song X; Tan J
Cytokine; 2014 Sep; 69(1):6-13. PubMed ID: 25022956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
